{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T12:02:47Z","timestamp":1770984167790,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81370637"],"award-info":[{"award-number":["81370637"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s00432-017-2353-2","type":"journal-article","created":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T15:57:33Z","timestamp":1488383853000},"page":"1013-1022","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy"],"prefix":"10.1007","volume":"143","author":[{"given":"Qian","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai-Bo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert Peter","family":"Gale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,1]]},"reference":[{"issue":"6","key":"2353_CR1","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.3109\/10428194.2011.560310","volume":"52","author":"Z Aziz","year":"2011","unstructured":"Aziz Z, Iqbal J, Aaqib M, Akram M, Saeed A (2011) Assessment of quality of life with imatinibmesylate as first-line treatment in chronic phase-chronic myeloid leukemia. Leuk Lymphoma 52(6):1017\u20131023","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2353_CR2","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","volume":"34","author":"E Basch","year":"2016","unstructured":"Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P et al (2016) Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol 34(6):557\u2013565","journal-title":"J Clin Oncol"},{"issue":"24","key":"2353_CR3","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bj\u00f6rkholm M, Dickman PW, H\u00f6glund M, Lambert PC, Andersson TM (2016) Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol 34(24):2851\u20132857","journal-title":"J Clin Oncol"},{"issue":"11","key":"2353_CR4","doi-asserted-by":"crossref","first-page":"4487","DOI":"10.1007\/s00520-016-3286-z","volume":"24","author":"M Breccia","year":"2016","unstructured":"Breccia M, Graffigna G, Galimberti S, Iurlo A, Pungolino E, Pizzuti M et al (2016) Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis. Support Care Cancer 24(11):4487\u20134493","journal-title":"Support Care Cancer"},{"issue":"5","key":"2353_CR5","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.clml.2016.02.002","volume":"16","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Lipton JH, Miller CB, Busque L, Akard LP, Pinilla-Ibarz J et al (2016) Evaluating the impact of a switch to nilotinib on imatinib-related chronic low-grade adverse events in patients with CML-CP: the ENRICH study. Clin Lymphoma Myeloma Leuk 16(5):286\u2013296","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"17","key":"2353_CR6","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","volume":"118","author":"F Efficace","year":"2011","unstructured":"Efficace F, Baccarani M, Breccia M, Alimena G, Rosti G, Cottone F et al (2011) GIMEMA. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 118(17):4554\u20134560","journal-title":"Blood"},{"issue":"9","key":"2353_CR7","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s00277-012-1458-6","volume":"91","author":"F Efficace","year":"2012","unstructured":"Efficace F, Breccia M, Saussele S, Kossak-Roth U, Cardoni A, Caocci G et al (2012) Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group. Ann Hematol 91(9):1371\u20131381","journal-title":"Ann Hematol"},{"issue":"7","key":"2353_CR8","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/leu.2013.51","volume":"27","author":"F Efficace","year":"2013","unstructured":"Efficace F, Baccarani M, Breccia M, Cottone F, Alimena G, Deliliers GL et al (2013) Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia 27(7):1511\u20131519","journal-title":"Leukemia"},{"issue":"3","key":"2353_CR9","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s11136-013-0523-5","volume":"23","author":"F Efficace","year":"2014","unstructured":"Efficace F, Baccarani M, Breccia M, Saussele S, Abel G, Caocci G et al (2014) International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24. Qual Life Res 23(3):825\u2013836","journal-title":"Qual Life Res"},{"issue":"2","key":"2353_CR10","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00277-015-2541-6","volume":"95","author":"F Efficace","year":"2016","unstructured":"Efficace F, Rosti G, Breccia M, Cottone F, Giesinger JM, Stagno F et al (2016a) The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia. Ann Hematol 95(2):211\u2013219","journal-title":"Ann Hematol"},{"issue":"12","key":"2353_CR11","doi-asserted-by":"crossref","first-page":"4887","DOI":"10.1007\/s00520-016-3344-6","volume":"24","author":"F Efficace","year":"2016","unstructured":"Efficace F, Breccia M, Cottone F, Okumura I, Doro M, Riccardi F et al (2016b) Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapies. Support Care Cancer 24(12):4887\u20134894","journal-title":"Support Care Cancer"},{"issue":"7","key":"2353_CR12","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jnci\/djr060","volume":"103","author":"C Gambacorti-Passerini","year":"2011","unstructured":"Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C et al (2011) Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 103(7):553\u2013561","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"2353_CR13","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1185\/03007995.2014.944973","volume":"30","author":"Gu\u00b4erinA","year":"2014","unstructured":"Gu\u00b4erinA, Chen L, Ionescu-Ittu R, Marynchenko M, Nitulescu R, Hiscock R (2014) Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase. Curr Med Res 30(11):2317\u20132328","journal-title":"Curr Med Res"},{"issue":"8","key":"2353_CR14","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.3109\/10428194.2013.854886","volume":"55","author":"JF Guest","year":"2014","unstructured":"Guest JF, Gray EJ, Szczudlo T, Magestro M (2014) Utility values for specific chronic myeloid leukemia chronic phase health states from the general public in the United Kingdom. Leuk Lymphoma 55(8):1870\u20131875","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2353_CR15","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/ejh.12743","volume":"97","author":"N Gunnarsson","year":"2016","unstructured":"Gunnarsson N, Sandin F, H\u00f6glund M, Stenke L, Bj\u00f6rkholm M, Lambe M et al (2016) Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence. Eur J Haematol 97(4):387\u2013392","journal-title":"Eur J Haematol"},{"issue":"11","key":"2353_CR16","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1200\/JCO.2003.12.154","volume":"21","author":"EA Hahn","year":"2003","unstructured":"Hahn EA, Glendenning GA, Sorensen MV, Hudgens SA, Druker BJ, Guilhot F et al (2003) IRIS Investigators. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol 21(11):2138\u20132146","journal-title":"J Clin Oncol"},{"issue":"8","key":"2353_CR17","first-page":"2113","volume":"22","author":"N Hamerschlak","year":"2014","unstructured":"Hamerschlak N, de Souza C, Cornacchioni AL, Pasquini R, Tabak D, Spector N, Steagall M (2014) Quality of life of chronic myeloid leukemia patients in Brazil: ability to work as a key factor. Support Care Cancer 22(8):2113\u20132118","journal-title":"Support Care Cancer"},{"key":"2353_CR18","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/1477-7525-11-167","volume":"11","author":"I Hirji","year":"2013","unstructured":"Hirji I, Gupta S, Goren A, Chirovsky DR, Moadel AB, Olavarria E et al (2013) Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient\u2019s perspective. Health Qual Life Outcomes 11:167","journal-title":"Health Qual Life Outcomes"},{"issue":"12","key":"2353_CR19","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.26679","volume":"118","author":"X Huang","year":"2012","unstructured":"Huang X, Cortes J, Kantarjian H (2012) Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 118(12):3123\u20133127","journal-title":"Cancer"},{"issue":"4","key":"2353_CR20","doi-asserted-by":"crossref","first-page":"156","DOI":"10.4103\/2279-042X.128145","volume":"2","author":"P Jain","year":"2013","unstructured":"Jain P, Das VN, Ranjan A, Chaudhary R, Pandey K (2013) Comparative study for the efficacy, safety and quality of life in patients of chronic myeloid leukemia treated with Imatinib or Hydroxyurea. J Res Pharm Pract 2(4):156\u2013161","journal-title":"J Res Pharm Pract"},{"key":"2353_CR21","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.2147\/PPA.S92125","volume":"9","author":"M Kek\u00e4le","year":"2015","unstructured":"Kek\u00e4le M, Peltoniemi M, Airaksinen M (2015) Patient-reported adverse drug reactions and their influence on adherence and quality of life of chronic myeloid leukemia patients on per oral tyrosine kinase inhibitor treatment. Patient Prefer Adherence 9:1733\u20131740","journal-title":"Patient Prefer Adherence"},{"issue":"7","key":"2353_CR22","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00432-016-2155-y","volume":"142","author":"M Lauseker","year":"2016","unstructured":"Lauseker M, Gerlach R, Tauscher M, Hasford J (2016) Improved survival boosts the prevalence of chronic myeloid leukemia: predictions from a population-based study. J Cancer Res Clin Oncol 142(7):1441\u20131447","journal-title":"J Cancer Res Clin Oncol"},{"key":"2353_CR23","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/jech.57.4.259","volume":"57","author":"L Li","year":"2003","unstructured":"Li L, Wang HM, Shen Y (2003) Chinese SF-36 Health Survey: translation, cultural adaptation, validation, and normalisation. J Epidemiol Community Health 57:259\u2013263","journal-title":"J Epidemiol Community Health"},{"key":"2353_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30325","author":"RA Mesa","year":"2016","unstructured":"Mesa RA, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S et al (2016) Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists\/oncologists in the United States: findings from the MPN landmark survey. Cancer. doi:\n10.1002\/cncr.30325\n\n (Epub ahead of print] PubMed PMID: 27690182)","journal-title":"Cancer"},{"issue":"4","key":"2353_CR25","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/bmt.2013.232","volume":"49","author":"XD Mo","year":"2014","unstructured":"Mo XD, Jiang Q, Xu LP, Liu DH, Liu KY, Jiang B et al (2014) Health-related quality of life of patients with newly diagnosed chronic myeloid leukemia treated with allogeneic hematopoietic SCT versus imatinib. Bone Marrow Transplant 49(4):576\u2013580","journal-title":"Bone Marrow Transplant"},{"key":"2353_CR26","unstructured":"National Comprehensive Cancer Network, NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia Version 1 (2016) Fort Washington PA. National Comprehensive Care Network. \nhttp:\/\/www.nccn.Org\/professionals\/physician_gls\/pdf\/cml.pdf\n\n. Accessed 26 March 2016"},{"issue":"2","key":"2353_CR27","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3109\/10428194.2015.1049166","volume":"57","author":"JS Park","year":"2016","unstructured":"Park JS, Lee SE, Jeong SH, Jang EJ, Choi MY, Kim HJ et al (2016) Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients. Leuk Lymphoma 57(2):341\u2013347","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2353_CR28","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s00520-012-1630-5","volume":"21","author":"KM Phillips","year":"2013","unstructured":"Phillips KM, Pinilla-Ibarz J, Sotomayor E, Lee MR, Jim HS, Small BJ et al (2013) Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Support Care Cancer 21(4):1097\u20131103","journal-title":"Support Care Cancer"},{"issue":"5","key":"2353_CR29","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","volume":"2","author":"K Sasaki","year":"2015","unstructured":"Sasaki K, Strom SS, O\u2019Brien S, Jabbour E, Ravandi F, Konopleva M et al (2015) Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol 2(5):e186\u201393","journal-title":"Lancet Haematol"},{"issue":"4","key":"2353_CR30","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.leukres.2011.10.011","volume":"36","author":"PC Trask","year":"2012","unstructured":"Trask PC, Cella D, Besson N, Kelly V, Masszi T, Kim DW (2012) Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia. Leuk Res 36(4):438\u2013442","journal-title":"Leuk Res"},{"issue":"1","key":"2353_CR31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.leukres.2012.09.013","volume":"37","author":"PC Trask","year":"2013","unstructured":"Trask PC, CellaD, Powell C, Reisman A, Whiteley J, Kelly V (2013) Health-related quality of life in chronic myeloid leukemia. Leuk Res 37(1):9\u201313","journal-title":"Leuk Res"},{"key":"2353_CR32","first-page":"AS264","volume":"33","author":"JE Ware","year":"1995","unstructured":"Ware JE, Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A (1995) Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the medical outcomes study. Med Care 33:AS264\u2013A79","journal-title":"Med Care"},{"issue":"8","key":"2353_CR33","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1185\/03007995.2016.1174108","volume":"2","author":"J Whiteley","year":"2016","unstructured":"Whiteley J, ReismanA, Shapiro M, Cortes J, Cella D (2016) Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure. Curr Med Res Opin 2(8):1325\u20131334","journal-title":"Curr Med Res Opin"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-017-2353-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-017-2353-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-017-2353-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,11]],"date-time":"2017-05-11T15:43:40Z","timestamp":1494517420000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-017-2353-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,1]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["2353"],"URL":"https:\/\/doi.org\/10.1007\/s00432-017-2353-2","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,1]]}}}